List view / Grid view
8 October 2013 | By GlaxoSmithKline
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases...
8 October 2013 | By Tecan
Tecan announces the European launch of its Tecan Academy web-based training tool...
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
7 October 2013 | By AstraZeneca
As previously announced, the acquisition bolsters MedImmune’s oncology pipeline...
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
7 October 2013 | By Mengele PMC
Lab will allow development of even more powerful supercomputers for life sciences research...
7 October 2013 | By Publicis Life Brands Resolute
Multi-stakeholder collaboration at the heart of Janssen Health Policy Centre...
7 October 2013 | By Publicis Life Brands Resolute
New report presents unique statistics on health R&D in the European Union...
7 October 2013 | By Nobel Prize
The 2013 Nobel Prize honours three scientists who have solved the mystery of how the cell organizes its transport system...
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
